Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P54756
UPID:
EPHA5_HUMAN
Alternative names:
Brain-specific kinase; EPH homology kinase 1; EPH-like kinase 7
Alternative UPACC:
P54756; Q7Z3F2
Background:
Ephrin type-A receptor 5 (EPHA5), also known as Brain-specific kinase, EPH homology kinase 1, and EPH-like kinase 7, is a receptor tyrosine kinase that engages in bidirectional signaling via GPI-anchored ephrin-A family ligands. This interaction is pivotal for axon guidance during development, influencing the formation of the retinotectal, entorhino-hippocampal, and hippocamposeptal pathways. Moreover, EPHA5, in concert with EFNA5, contributes to synaptic plasticity in the adult brain by regulating synaptogenesis. Its role extends to the pancreatic islet cells, where it mediates glucose-stimulated insulin secretion.
Therapeutic significance:
Understanding the role of Ephrin type-A receptor 5 could open doors to potential therapeutic strategies.